CVS Health and FTC Staff Reach Consensus on Proposed Insulin Settlement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CVS?
Source: Barron's
Proposed Agreement: CVS Health and the Federal Trade Commission (FTC) staff have proposed an agreement to address litigation regarding insulin pricing.
Accusations Against PBMs: The FTC accused pharmacy-benefit managers (PBMs) of artificially inflating the prices of insulin.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 70.080
Low
91.00
Averages
96.71
High
105.00
Current: 70.080
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Launches Community Pharmacies to Enhance Access
- Community Pharmacy Openings: CVS Health plans to open nearly 20 pharmacy-only locations in 2026, starting with one in Chicago, aimed at enhancing residents' access to medications and immunization services, thereby improving community health service accessibility.
- Customized Offerings: The new pharmacies will feature a tailored selection of over-the-counter products, with an average footprint of 3,000 square feet, ensuring patients can conveniently access prescription medications and professional pharmacist advice, which is expected to boost patient satisfaction and loyalty.
- Diverse Pharmacy Formats: By introducing pharmacy-only locations alongside traditional pharmacies, in-store pharmacies, and MinuteClinics, CVS aims to meet the varied health needs of different communities while optimizing its retail footprint to adapt to industry shifts.
- Importance of Face-to-Face Interactions: According to the 2025 CVS Health Rx Report, 80% of patients prefer in-person pharmacy care, and CVS is ensuring patients have multiple service options to choose from based on their individual needs, thereby enhancing overall service delivery.
See More
CVS Health to Open Pharmacy-Only Locations in Multiple Communities in 2026, Alongside New Site in Chicago
- Pharmacy Locations: CVS Health is planning to open pharmacy-only locations in several communities in 2026, in addition to a new site in Chicago.
- Community Focus: The initiative aims to enhance access to pharmacy services in various neighborhoods, reflecting a commitment to community health.
See More
CVS Health Launches Its First Pharmacy-Only Location in Chicago
CVS Pharmacy Launch: CVS has opened its first pharmacy-only location in Chicago, marking a new approach to its retail strategy.
Focus on Accessibility: The new pharmacy aims to enhance accessibility to pharmaceutical services for the local community.
Innovative Services: This location will offer a range of services tailored to meet the needs of patients, including medication management and consultations.
Expansion Plans: CVS plans to evaluate the success of this model for potential expansion to other urban areas in the future.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
CVS Health and FTC Staff Reach Consensus on Proposed Insulin Settlement
Proposed Agreement: CVS Health and the Federal Trade Commission (FTC) staff have proposed an agreement to address litigation regarding insulin pricing.
Accusations Against PBMs: The FTC accused pharmacy-benefit managers (PBMs) of artificially inflating the prices of insulin.
See More
CVS Health Stock Rebounds, Analysts Bullish on Future Outlook
- Stock Rebound: CVS Health's stock rose 2.45% to $73.04 on Tuesday afternoon after six consecutive losing sessions, indicating a gradual recovery in market confidence regarding its future performance.
- Relative Performance: Over the past six trading days, CVS's stock has declined by 6.36%, compared to a mere 0.77% drop in the S&P 500, suggesting that CVS's performance has significantly lagged behind the broader market, potentially attracting investor scrutiny.
- Analyst Ratings: Seeking Alpha analyst Edmund Ingham rated CVS as a Buy, forecasting growth driven by margin recovery and attractive valuation metrics for 2026-2027, despite risks such as high leverage and regulatory uncertainty.
- FTC Settlement: CVS reached a settlement with the U.S. Federal Trade Commission regarding allegations tied to insulin pricing by its PBM unit, Caremark, demonstrating the company's proactive approach to compliance issues.
See More
CVS Launches Community Pharmacies to Enhance Access
- Community Pharmacy Openings: CVS Health plans to open nearly 20 pharmacy-only locations in 2026, starting with one in Chicago, aimed at enhancing residents' access to medications and immunization services, thereby improving community health service accessibility.
- Customized Offerings: The new pharmacies will feature a tailored selection of over-the-counter products, with an average footprint of 3,000 square feet, ensuring patients can conveniently access prescription medications and professional pharmacist advice, which is expected to boost patient satisfaction and loyalty.
- Diverse Pharmacy Formats: By introducing pharmacy-only locations alongside traditional pharmacies, in-store pharmacies, and MinuteClinics, CVS aims to meet the varied health needs of different communities while optimizing its retail footprint to adapt to industry shifts.
- Importance of Face-to-Face Interactions: According to the 2025 CVS Health Rx Report, 80% of patients prefer in-person pharmacy care, and CVS is ensuring patients have multiple service options to choose from based on their individual needs, thereby enhancing overall service delivery.
See More
CVS Health to Open Pharmacy-Only Locations in Multiple Communities in 2026, Alongside New Site in Chicago
- Pharmacy Locations: CVS Health is planning to open pharmacy-only locations in several communities in 2026, in addition to a new site in Chicago.
- Community Focus: The initiative aims to enhance access to pharmacy services in various neighborhoods, reflecting a commitment to community health.
See More
CVS Health Launches Its First Pharmacy-Only Location in Chicago
CVS Pharmacy Launch: CVS has opened its first pharmacy-only location in Chicago, marking a new approach to its retail strategy.
Focus on Accessibility: The new pharmacy aims to enhance accessibility to pharmaceutical services for the local community.
Innovative Services: This location will offer a range of services tailored to meet the needs of patients, including medication management and consultations.
Expansion Plans: CVS plans to evaluate the success of this model for potential expansion to other urban areas in the future.
See More
CVS Health Reaches Proposed Settlement with FTC on Insulin Pricing
- Settlement Progress: CVS Health's proposed settlement with the FTC is expected to be finalized in the coming weeks, modeled after a similar agreement with Cigna's Express Scripts, indicating the company's proactive stance on drug pricing transparency.
- Stock Price Reaction: Following the settlement news, CVS Health shares rose 2% on Tuesday, reflecting market optimism about the agreement, with analysts suggesting that this resolution will alleviate uncertainties in the pharmacy benefit management sector, thereby boosting investor confidence.
- Market Outlook: Leerink reiterated an 'Outperform' rating on CVS Health with a $98 price target, suggesting a potential upside of approximately 35% from Tuesday's closing price, indicating a positive market sentiment regarding the company's future performance.
- Cost Reduction for Patients: The settlement with the FTC is expected to lower patients' out-of-pocket costs for insulin and other drugs by up to $7 billion over the next decade, highlighting CVS's strategic importance in advocating for drug price rationalization.
See More
CVS Health and FTC Staff Reach Consensus on Proposed Insulin Settlement
Proposed Agreement: CVS Health and the Federal Trade Commission (FTC) staff have proposed an agreement to address litigation regarding insulin pricing.
Accusations Against PBMs: The FTC accused pharmacy-benefit managers (PBMs) of artificially inflating the prices of insulin.
See More
CVS Health Stock Rebounds, Analysts Bullish on Future Outlook
- Stock Rebound: CVS Health's stock rose 2.45% to $73.04 on Tuesday afternoon after six consecutive losing sessions, indicating a gradual recovery in market confidence regarding its future performance.
- Relative Performance: Over the past six trading days, CVS's stock has declined by 6.36%, compared to a mere 0.77% drop in the S&P 500, suggesting that CVS's performance has significantly lagged behind the broader market, potentially attracting investor scrutiny.
- Analyst Ratings: Seeking Alpha analyst Edmund Ingham rated CVS as a Buy, forecasting growth driven by margin recovery and attractive valuation metrics for 2026-2027, despite risks such as high leverage and regulatory uncertainty.
- FTC Settlement: CVS reached a settlement with the U.S. Federal Trade Commission regarding allegations tied to insulin pricing by its PBM unit, Caremark, demonstrating the company's proactive approach to compliance issues.
See More
